Pegasys peginterferon alfa-2a: Phase III data; U.S. NDA under review

Preliminary data from a 160-patient Phase III study showed that 3 Pegasys combination therapy regimens had a similar

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE